Cited by

• Cerebral oedema after subarachnoid haemorrhage. Pathogenetic significance of vasopressin.

  László FA, Varga C, Dóczi T. László FA, et al. Acta Neurochir (Wien). 1995;133(3-4):122-33. doi: 10.1007/BF01420062. Acta Neurochir (Wien). 1995. PMID: 8748754
• Oxytocin receptors expressed and coupled to Ca2+ signalling in a human vascular smooth muscle cell line.

  Yazawa H, Hirasawa A, Horie K, Saita Y, Iida E, Honda K, Tsujimoto G. Yazawa H, et al. Br J Pharmacol. 1996 Mar;117(5):799-804. doi: 10.1111/j.1476-5381.1996.tb15263.x. Br J Pharmacol. 1996. PMID: 8851493 Free PMC article.
• Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.

  Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A. Tsukada J, et al. Br J Pharmacol. 2001 Jul;133(5):746-54. doi: 10.1038/sj.bjp.0704117. Br J Pharmacol. 2001. PMID: 11429400 Free PMC article.
• Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

  Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, et al. Serradeil-Le Gal C, et al. J Clin Invest. 1993 Jul;92(1):224-31. doi: 10.1172/JCI116554. J Clin Invest. 1993. PMID: 8392086 Free PMC article.
• Molecular dynamics study of 4-OH-phenylacetyl- D-Y(Me)FQNRPR-NH2 selectivity to V1a receptor.

  Giełdoń A, Kaźmierkiewicz R, Slusarz R, Pasenkiewicz-Gierula M, Ciarkowski J. Giełdoń A, et al. J Mol Model. 2003 Dec;9(6):372-8. doi: 10.1007/s00894-003-0142-0. Epub 2003 Oct 7. J Mol Model. 2003. PMID: 14530927